Rheumatoid Arthritis

Demographic, psychosocial, and clinical factors—along with patient-provider relationships—all impact medication adherence and patient satisfaction with RA treatment.

Internal dysbiosis was present in 66% of patients at baseline and was more common among those with a disease duration of > 2 years.

Patients with RA reported worse outcomes for all PROMs compared with CSA or UA.

Patients receiving abatacept experienced smaller increases in mean IMT, max IMT, and plaque score compared with the csDMARD cohorts.

At the end of the trial, the study met its primary outcome, indicating therapeutic equivalence between the biosimilar (AVT05) and reference golimumab.

Thoracic ultrasound examination may be applicable as a screening method for interstitial lung disease in patients with RA and respiratory symptoms.

An extension study showed upadacitinib 15 mg and 30 mg for rheumatoid arthritis continues to be favorable, with many patients achieving remission.

Most (94%) anti-nucleocapsid positivity was linked to a self-reported COVID-19 infection within the prior 3 months.

Results of the SELECT-GCA study demonstrated approximately half of patients with giant cell arteritis treated with upadacitinib plus a steroid tapering regimen were able to achieve sustained remission through week 52.

Participants described the intervention as complete and coherent and would recommend this intervention to other patients.

A study found MRI treat-to-target strategy does not help bring RA patients to remission, even when also targeting the absence of osteitis alongside clinical remission.

Five barriers to adopting TNF therapeutic drug monitoring emerged among a cohort of experienced rheumatologists.

The median survival for triple therapy was longer compared with double therapy (15.1 months vs 9.6 months).

Obesity was linked to a lower likelihood of obtaining response to treatment during the 48-week follow-up period.

Exercise was beneficial in functional status for both patients with RA and spondyloarthritis.

Birthweight was significantly lower in women who were not treated with a TNF.

Receiving methotrexate and leflunomide within the 3 months prior to conception was linked to an increased rate of adverse pregnancy outcomes.

Between 2009 and 2020, the number of rheumatologists increased 23%, from 4557 to 5600.

Participants with an RA risk had various opinions on preventive measures, from being on board, needing to be swayed by a doctor, and fearing the intervention.

The analysis of NHANES 2005-2016 data found exposure to thiocyanate, either alone or in combination with perchlorate and nitrate, was associated with arthritis vulnerability and inflammation.

Despite being a rare occurrence, the infection was linked to deaths in 1 in 5 observed patients.

A new study found RA patients with concomitant Sjögren’s disease were more likely to fail TNFi treatment than the treatments of other mode of action biologics and JAKi.

A 6-week bodyweight exercise program led to improved muscle strength, range of motion, and physical fitness test results in female patients with RA.

A new study suggests patients with either rheumatoid arthritis or osteoarthritis may be at a higher genetic susceptibility to develop COPD.

A new study evaluated gender differences in physical functioning, sexual dysfunction, depression, fatigue, pain, and loneliness among RA patients using and not using methotrexate.

Findings suggest a positive association between valine, leucine, and isoleucine intake with RA risk, although total and individual dietary BCAA intake were not related to disease activity parameters.

New 5 year data from the phase 3 SELECT-COMPARE trial suggest a patient with RA not responding to adalimumab or upadacitinib may fare better switching to the other.

An analysis of data from more than 5 million people suggests rheumatic and immune-mediated diseases were associated with increased rates of childlessness and elevated risk of adverse pregnancy outcomes.

Participants with RA had a 1.66-fold greater risk of depression compared to participants without RA, a new study found.

After propensity score matching, patients with COVID-19 were at an increased risk for AIRD when compared with both uninfected controls and influenza-infected patients.